secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0000950170-23-006125
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio reports FY2022 net loss of $66.7M; RLYB212 achieves proof-of-concept in Phase 1b
--------------------------------------------------------------------------------

- Net loss for FY2022 was $66.7M ($2.09/share) vs $47.0M ($1.84/share) in 2021; Q4 loss $16.2M.
- RLYB212 Phase 1b proof-of-concept: single dose eliminated >90% of HPA-1a positive platelets; well-tolerated.
- Cash, equivalents, and marketable securities $169.0M as of Dec 31, 2022; runway into Q1 2025.
- RLYB211 discontinued; RLYB212 multi-dose cohort initiated, data expected Q4 2023.
- Jonathan Lieber appointed CFO effective Feb 1, 2023; follow-on offering raised ~$55M in Nov 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000095017023006125/0000950170-23-006125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000095017023006125/rlyb-20230306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-006125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer